Sandeep Sahay VIEW CLINICAL PROFILE

Sandeep Sahay, MD, MSc, ATSF

Associate Professor of Medicine, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Description of Research

Pulmonary Hypertension

Pulmonary Arterial Hypertension

Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Embolism

Interstitial Lung Diseases

Areas Of Expertise

Pulmonary fibrosis Pulmonary hypertension Pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension
Education & Training

MD
Active Clinical Trials

A Phase 2, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects with Pulmonary Arterial Hypertension (PAH)

NCT04266197


A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535


An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension (ASCENT Study) LTI-401

N/A


Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

NCT05776225


A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension (TROPOS Study)

N/A

Publications

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus
Brewer, J, Wilson, M, Coons, JC, Schmit, A, Whittenhall, ME, Kimber, A, Broderick, M, Lee, D, Patzlaff, N, Miller, C, Ataya, A, LaRoy, V, King, CS, Ravichandran, AK, Kingrey, JF & Sahay, S 2024, , Respiratory Medicine, vol. 231, 107734. https://doi.org/10.1016/j.rmed.2024.107734

Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis
Pulmonary Vascular Research Institute GoDeep Consortium 2024, , CHEST, vol. 166, no. 3, pp. 585-603. https://doi.org/10.1016/j.chest.2024.03.018

The evolution of the European risk stratification system for pulmonary arterial hypertension
Sahay, S & Benza, RL 2024, , The European respiratory journal, vol. 64, no. 3. https://doi.org/10.1183/13993003.00943-2024

Genetic Testing in Pulmonary Arterial Hypertension Evaluation: A Patient and Clinician Survey
Rice, JL, Austin, ED, Mathai, SC & Sahay, S 2024, , CHEST, vol. 165, no. 5, pp. 1224-1227. https://doi.org/10.1016/j.chest.2023.11.026

Recovery from kidney failure associated with chronic thromboembolic pulmonary hypertension following pulmonary thomboendarterectomy
Nassar, GM, Jameson, R, Sathiyaraj, S, Bidikian, N, Hernandez, NV & Sahay, S 2024, , Clinical Kidney Journal, vol. 17, no. 4, sfae047, pp. fae047. https://doi.org/10.1093/ckj/sfae047

Chronic Thromboembolic Pulmonary Hypertension
Estrada, RA, Auger, WR & Sahay, S 2024, , JAMA: The Journal of the American Medical Association, vol. 331, no. 11, pp. 972-973. https://doi.org/10.1001/jama.2023.24265

Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension
Sahay, S, Villasmil Hernandez, N, Wang, F, Wooten, M, Nguyen, DT, Fauvel, C, Benza, R & Graviss, EA 2024, , CHEST, vol. 166, no. 2, pp. 373-387. https://doi.org/10.1016/j.chest.2024.02.052

Rebuttal From Dr Sahay
Sahay, S 2024, , CHEST, vol. 165, no. 3, pp. 498-499. https://doi.org/10.1016/j.chest.2023.07.4230

Counterpoint: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? No
Sahay, S 2024, , CHEST, vol. 165, no. 3, pp. 494-496. https://doi.org/10.1016/j.chest.2023.07.4229

Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
TORREY Study Investigators 2024, , The Lancet Respiratory Medicine, vol. 12, no. 7, pp. 523-534. https://doi.org/10.1016/S2213-2600(24)00072-9

Tyvaso DPI: Drug-device characteristics and patient clinical considerations
McEvoy, C, Argula, R, Sahay, S, Shapiro, S, Eagan, C, Hickey, AJ, Smutney, C, Dillon, C, Winkler, T, Davis, BN, Broderick, M & Burger, C 2023, , Pulmonary Pharmacology and Therapeutics, vol. 83, 102266, pp. 102266. https://doi.org/10.1016/j.pupt.2023.102266, https://doi.org/10.1016/j.pupt.2023.102266

Impact on Pulmonary Hypertension Hemodynamic Classification Based on the Methodology Used to Measure Pulmonary Artery Wedge Pressure and Cardiac Output
Sahay, S, Lane, J, Sharpe, MG, Toth, D, Paul, D, Siuba, MT & Tonelli, AR 2023, , Annals of the American Thoracic Society, vol. 20, no. 12, pp. 1752-1759. https://doi.org/10.1513/AnnalsATS.202303-216OC

Tyvaso DPI: Drug-device characteristics and patient clinical considerations
McEvoy, C, Argula, R, Sahay, S, Shapiro, S, Eagan, C, Hickey, AJ, Smutney, C, Dillon, C, Winkler, T, Davis, BN, Broderick, M & Burger, C 2023, , Pulmonary Pharmacology and Therapeutics, vol. 83, 102266. https://doi.org/10.1016/j.pupt.2023.102266

Impact on Pulmonary Hypertension Hemodynamic Classification Based on the Methodology Used to Measure Pulmonary Artery Wedge Pressure and Cardiac Output
Sahay, S, Lane, J, Sharpe, MG, Toth, D, Paul, D, Siuba, MT & Tonelli, AR 2023, , Annals of the American Thoracic Society, vol. 20, no. 12, pp. 1752-1759. https://doi.org/10.1513/AnnalsATS.202303-216OC

Genetic Testing in Pulmonary Arterial Hypertension Evaluation: A Patient and Clinician Survey
Rice, JL, Austin, ED, Mathai, SC & Sahay, S 2023, , CHEST. https://doi.org/10.1016/j.chest.2023.11.026

End-of-Life and Palliative Care Issues for Patients Living with Pulmonary Arterial Hypertension: Barriers and Opportunities
Ali, HJ & Sahay, S 2023, , Seminars in Respiratory and Critical Care Medicine, vol. 44, no. 6, pp. 866-876. https://doi.org/10.1055/s-0043-1770124

Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor
Ali, HJR, Thomas, J, Sahay, S & Guha, A 2023, , Pulmonary Circulation, vol. 13, no. 4, e12303, pp. e12303. https://doi.org/10.1002/pul2.12303

Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group
Morland, K, Gerges, C, Elwing, J, Visovatti, SH, Weatherald, J, Gillmeyer, KR, Sahay, S, Mathai, SC, Boucly, A, Williams, PG, Harikrishnan, S, Minty, EP, Hobohm, L, Jose, A, Badagliacca, R, Lau, EMT, Jing, ZC, Vanderpool, RR, Fauvel, C, Leonidas Alves, J, Strange, G, Pulido, T, Qian, J, Li, M, Mercurio, V, Zelt, JGE, Moles, VM, Cirulis, MM, Nikkho, SM, Benza, RL & Elliott, CG 2023, , Pulmonary Circulation, vol. 13, no. 4, e12317, pp. e12317. https://doi.org/10.1002/pul2.12317, https://doi.org/10.1002/pul2.12317

Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group
Morland, K, Gerges, C, Elwing, J, Visovatti, SH, Weatherald, J, Gillmeyer, KR, Sahay, S, Mathai, SC, Boucly, A, Williams, PG, Harikrishnan, S, Minty, EP, Hobohm, L, Jose, A, Badagliacca, R, Lau, EMT, Jing, ZC, Vanderpool, RR, Fauvel, C, Leonidas Alves, J, Strange, G, Pulido, T, Qian, J, Li, M, Mercurio, V, Zelt, JGE, Moles, VM, Cirulis, MM, Nikkho, SM, Benza, RL & Elliott, CG 2023, , Pulmonary Circulation, vol. 13, no. 4, e12317. https://doi.org/10.1002/pul2.12317

Tobacco, Second-Hand Smoke and Cancer
Pinkaew, D, Dammad, T, Bitar, M, Sahay, S & Folz, RJ 2023, . in EH Bernicker (ed.), Environmental Oncology : Theory and Impact. Springer, pp. 119-145. https://doi.org/10.1007/978-3-031-33750-5_5

VIEW FULL PUBLICATIONS